Abstract
Dainippon Sumitomo Pharma (DSP) is a research-based pharmaceutical company,
headquartered in Osaka, which has resulted from the merger of Dainippon
Pharmaceutical (which acts as the surviving company) and Sumitomo
Pharmaceutical (a division of Sumitomo Chemical). This report provides a full
review of the company's activities together with sales forecasts for key
products to 2010.
In the first nine months of fiscal 2005, Dainippon Sumitomo Pharma's net sales
rose by 5.6% compared to the same 2004 period, to ¥ 84.7 billion. Net income
rose by 51.6% to ¥ 4 billion, whilst operating income rose by 113% to ¥ 9.0
billion.
R&D Pipeline Overview
- Lonasen is an antipsychotic that features a completely innovative
chemical structure because of its potential to block both dopamine D2 and
5-HT2 receptors. It is awaiting approval in the US.
- Zonisamide has been filed in the US for the treatment of
Parkinson's disease, and is in late stage Phase III trials for this indication
in Japan.
- AS-3201 is currently in Phase III trials in the US and Canada and
Phase IIa trials in Japan for diabetic neuropathy. A preliminary agreement has
been signed with Kyorin Pharmaceutical related to the joint development and
co-marketing of the product in Japan.
- AC-3933 is a benzodiazepine receptor inverse agonist with a novel
mechanism of action that is expected to improve memory loss. Phase IIa trials
have been completed in Europe in tablet formulation and it is under
preparation for Phase IIa trials in the US.
Major Products Forecast to 2010
- Klaracid (Anti-infective)
- Meropen (Anti-infective)
- Gasmotin (Gastrointestinal)
- Ebastel (Anti-allergenic
- Prorenal (Cardiovascular)
- Almodin (Cardiovascular)
- Zyrtec (Anti-allergenic)
- Sumiferon (Hormone)
- Growject (Hormone)
- Tagamet (Gastrointestinal)
- Excegran (CNS)
- Almarl (Cardiovascular)
| 
View Cart
